SCHEDULE: Soleus Capital Discloses Inspire Medical Systems Stake

Soleus Capital Master Fund, L.P. and associated entities have reported beneficial ownership of 6.7% of Inspire Medical Systems, Inc. common stock as of June 30, 2026.

Summary

• Soleus Capital Master Fund, L.P., along with related entities Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, have filed a Schedule 13G.
• This filing indicates a change in beneficial ownership of Inspire Medical Systems, Inc. common stock.
• As of June 30, 2026, the aggregate beneficial ownership is reported as 1,931,436 shares, representing 6.7% of the class.
• The shares are held directly by Soleus Capital Master Fund, L.P.
• The filing clarifies that while various entities and Guy Levy disclaim beneficial ownership beyond determining Section 13(d) obligations, they are involved in the management and control structure.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports a change in beneficial ownership without providing new operational or financial performance data.

Positives

• Increased investor interest indicated by the filing, potentially signaling confidence in the company's long-term prospects.
• The reporting entities have a significant stake, suggesting a substantial investment in Inspire Medical Systems.

Negatives

• The filing does not provide any new operational or financial performance data for Inspire Medical Systems, limiting insight into the company's current health.
• The disclaimer of beneficial ownership by certain entities and individuals, while standard for such filings, can create ambiguity regarding ultimate control.

Risks

• Potential for increased market volatility if Soleus Capital decides to significantly alter its stake.
• The filing does not disclose the investment strategy or intent behind acquiring this stake, leaving future actions uncertain.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Inspire Medical Systems' future performance. It solely reports on beneficial ownership.

Management Comments

• Each of SCG, Soleus Capital, LLC, SCM, Soleus GP and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, as amended (the "Exchange Act"), and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes. For a medical device company like Inspire Medical Systems, significant changes in beneficial ownership can sometimes precede activist campaigns or strategic shifts, though this filing does not suggest such intent.

Stakeholder Impact

• Shareholders: May view the increased stake by Soleus Capital as a positive sign of investor confidence, or as a potential precursor to future strategic actions.
• Management: Will be aware of a significant institutional investor's holdings, which could influence future strategic decisions or shareholder engagement.

Next Steps

• Monitor future filings from Soleus Capital and its associated entities for any changes in their stake in Inspire Medical Systems.
• Observe Inspire Medical Systems' operational and financial performance for any impact related to significant shareholder positions.

Key Dates

Keywords

Inspire Medical Systems, Schedule 13G, Beneficial Ownership, Soleus Capital, Investment Management, Securities Exchange Act, Common Stock, Cayman Islands